Johnson & Johnson $JNJ Stock: Inspire Trust Co. N.A. Decreases Holdings

Inspire Trust Co. N.A. lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,500 shares of the company’s stock after selling 3,000 shares during the quarter. Inspire Trust Co. N.A.’s holdings in Johnson & Johnson were worth $7,545,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. CKW Financial Group increased its stake in Johnson & Johnson by 0.9% during the third quarter. CKW Financial Group now owns 4,269 shares of the company’s stock valued at $1,104,000 after purchasing an additional 37 shares during the last quarter. Silver Coast Investments LLC lifted its position in shares of Johnson & Johnson by 3.8% in the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock worth $271,000 after buying an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV lifted its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock worth $1,630,000 after buying an additional 39 shares during the last quarter. Triumph Capital Management boosted its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock valued at $643,000 after buying an additional 39 shares during the period. Finally, Kwmg LLC boosted its holdings in shares of Johnson & Johnson by 1.7% in the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company’s stock valued at $631,000 after buying an additional 39 shares during the period. Institutional investors own 69.55% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Oncology sales rose 16.8% to $22 billion in the first nine months of 2026, supported by established cancer drugs and new launches. Continued growth in this business could bolster revenue. J&J’s Oncology Sales Surge So Far in 2026: What Lies Ahead?
• Positive Sentiment: CAPLYTA met the primary and key secondary endpoints in a second Phase 3 study for bipolar mania, with improvement reported as early as Day 3. J&J said the two positive studies will support a planned U.S. FDA submission, adding to the drug’s potential uses. J&J eyes US nod for Caplyta in bipolar mania after second trial win
• Positive Sentiment: Investigational drug ICOTYDE met the primary endpoint in a Phase 3 trial for psoriatic arthritis, adding another encouraging pipeline result that could support future growth if confirmed and approved. Johnson & Johnson Says Icotyde in Psoriatic Arthritis Disease Meets Primary Endpoint in Phase 3 Study
• Neutral Sentiment: A valuation analysis questioned whether JNJ’s price reflects the cash flow it may generate, noting its 108.1% return over three years. It raises a caution for investors but does not establish that the shares are overvalued. Is Johnson & Johnson (JNJ) Below Fair Value On Cash Flow?
• Negative Sentiment: Pomerantz LLP announced an investigation into claims on behalf of JNJ investors. The notice provides few details and is not a finding of wrongdoing, but it introduces potential legal uncertainty. Investor Alert: Pomerantz Law Firm Investigates Claims

Johnson & Johnson Stock Performance

JNJ opened at $280.90 on Wednesday. The business’s 50 day moving average is $266.49 and its 200-day moving average is $248.93. The stock has a market cap of $676.21 billion, a PE ratio of 42.56, a price-to-earnings-growth ratio of 2.79 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $189.05 and a twelve month high of $283.25.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same period in the prior year, the company posted $2.80 EPS. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on JNJ. Johnson Rice lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Evercore set a $300.00 target price on Johnson & Johnson in a research report on Tuesday, October 20th. Citigroup raised their target price on Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research note on Wednesday, July 15th. Finally, Erste Group Bank downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $275.92.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.